We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+19.43%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.75B
AUM Growth
+$77.9M
Cap. Flow
-$78.7M
Cap. Flow %
-4.49%
Top 10 Hldgs %
55.92%
Holding
150
New
22
Increased
25
Reduced
39
Closed
26

Top Buys

Rank Stock Value
1
PTON icon
Peloton Interactive
PTON
+$15.1M
2
TRML
Tourmaline Bio
TRML
+$10.2M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$6.91M
4
EHTH icon
eHealth
EHTH
+$6.1M
5
CONN
Conn's Inc.
CONN
+$6.03M

Top Sells

Rank Stock Value
1
ESTA icon
Establishment Labs
ESTA
+$20.3M
2
SLNO
Soleno Therapeutics
SLNO
+$20.2M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$19.5M
4
LXFR icon
Luxfer Holdings
LXFR
+$10.1M
5
CYTK icon
Cytokinetics
CYTK
+$9.19M

Sector Composition

Rank Sector Weight
1 Healthcare 36.87%
2 Consumer Discretionary 8.07%
3 Financials 4.11%
4 Communication Services 3.43%
5 Technology 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SSKN
101
DELISTED
Strata Skin Sciences
SSKN
$1.17M 0.07%
308,982
-3,831
-1% -$20K
PLCE icon
102
Children's Place
PLCE
$58.9M
$1.15M 0.07%
+100,000
New +$1.89M
SGRP
103
DELISTED
SPAR Group
SGRP
$897K 0.05%
879,189
– –
GOSS icon
104
Gossamer Bio
GOSS
$86M
$794K 0.05%
672,856
– –
FBIO icon
105
Fortress Biotech
FBIO
$87M
$556K 0.03%
278,152
-94,410
-25% -$188K
PERF icon
106
Perfect Corp
PERF
$189M
$496K 0.03%
+200,000
New +$501K
EVOK
107
DELISTED
Evoke Pharma
EVOK
$412K 0.02%
+56,250
New +$478K
ANTX icon
108
AN2 Therapeutics
ANTX
$216M
$319K 0.02%
98,278
-150,000
-60% -$1.63M
LADR
109
Ladder Capital
LADR
$1.25B
$285K 0.02%
25,631
– –
EWTX icon
110
Edgewise Therapeutics
EWTX
$4.89B
$244K 0.01%
+13,371
New +$213K
APTO
111
DELISTED
Aptose Biosciences, Inc.
APTO
$147K 0.01%
2,951
-1,053
-26% -$60.2K
LUCD icon
112
Lucid Diagnostics
LUCD
$188M
$132K 0.01%
149,698
– –
BMTX
113
DELISTED
BM Technologies, Inc.
BMTX
$125K 0.01%
76,034
– –
TACT icon
114
Transact Technologies
TACT
$58.6M
$125K 0.01%
23,930
-4,197
-15% -$29.1K
XGN icon
115
Exagen
XGN
$165M
$118K 0.01%
74,306
-22,818
-23% -$44.3K
RNLX
116
DELISTED
Renalytix plc American Depositary Shares
RNLX
$101K 0.01%
+117,644
New +$80.6K
CUE icon
117
Cue Biopharma
CUE
$109M
$50.4K ﹤0.01%
890
– –
GFAIW icon
118
Guardforce AI Warrant
GFAIW
$60K
$50.3K ﹤0.01%
154,205
– –
GMDA
119
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$28.9K ﹤0.01%
800,000
– –
TCBPW
120
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
$4.71K ﹤0.01%
235,294
– –
HURA
121
TuHURA Biosciences
HURA
$137M
$1.28K ﹤0.01%
365
-264
-42% -$1.06K
ARHS icon
122
Arhaus
ARHS
$1.42B
$15 ﹤0.01%
+1
New +$13
AMLX icon
123
Amylyx Pharmaceuticals
AMLX
$2.6B
– –
-620,110
Closed -$9.13M
CDTX
124
DELISTED
Cidara Therapeutics
CDTX
– –
-77,337
Closed -$1.23M
MBAI
125
Check-Cap
MBAI
$10.2M
– –
-33,400
Closed -$69.5K
2 3 4
5
6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Nantahala Capital Management held 150 positions worth $1.75B, up 4.7% from $1.67B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Nantahala Capital Management withdrew a net $78.7M in Q1 2024, closing 26 positions and reducing 39 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $19.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Nantahala Capital Management opened a new position in Eagle Pharmaceuticals, Inc. worth $6.6M.

  • Nantahala Capital Management's largest Q1 2024 buy was Eagle Pharmaceuticals, Inc.: 1,258,762 shares worth $6.6M.
  • Nantahala Capital Management added most to Peloton Interactive in Q1 2024, an estimated $15.1M increase.
  • Nantahala Capital Management's biggest Q1 2024 reduction was Establishment Labs, cutting an estimated $20.3M.
  • Nantahala Capital Management fully exited iShares Russell 2000 ETF in Q1 2024, selling an estimated $19.5M.
  • Nantahala Capital Management's ten largest holdings make up 56% of its $1.75B portfolio in Q1 2024.
  • Nantahala Capital Management opened 22 new positions and closed 26 in Q1 2024.
  • Nantahala Capital Management's portfolio value rose 4.7% quarter-over-quarter to $1.75B.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.